- CEO
- Stéphane Ledermann
- Full Time Employees
- 36
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 3, Avenue George V Paris IF France 75008
- IPO Date
- Apr 27, 2010
- Business
- AB Science S.A. AB Science S.A. (AB.PA) is a French clinical-stage pharmaceutical company that researches, develops, and commercializes protein kinase inhibitors and targeted therapies for diseases with high unmet medical needs in humans and veterinary medicine; its lead product, masitinib, a highly selective tyrosine kinase inhibitor, targets oncology, inflammatory diseases such as severe asthma and ALS, neurological disorders including multiple sclerosis, and viral diseases, while registered for veterinary use in mast cell tumors; the company also advances AB8939, a new generation microtubule destabilizer, primarily in acute myeloid leukemia with ongoing phase 1 expansion studies in combination with venetoclax. Founded in 2001 and headquartered at 3 Avenue George V in Paris, France, AB Science S.A. operates globally through clinical trials across Europe and North America, supported by a U.S. subsidiary in New Jersey, with nearly 40 employees focused on R&D and listed on Euronext Paris since 2010. In recent developments, the company completed multiple private placements totaling over EUR 9 million between May and October 2025, including EUR 2.8 million in October to fund AB8939 phase 1 completion and expansion in AML, alongside EUR 1.8 million in May, EUR 1.925 million in July, and EUR 2.55 million in August, securing financing beyond 12 months; it received regulatory approvals in 2025 from European countries for AB8939 phase I/II confirmatory studies and masitinib ALS phase 3 initiation, while extending Masivet shelf-life to four years via EMA approval.